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pesticides contribute to 
a substantial burden of 
mortality and morbidity from self-
poisoning, particularly in developing 
countries. Such poisonings are 
associated with several syndromes, 
including acute cholinergic crises, the 
intermediate syndrome (IMS), and 
organophosphate-induced delayed 
neuropathy. In a study published 
in PLoS Medicine, Jayawardane and 
colleagues begin to scientifically 
characterize a specific constellation 
of signs and symptoms seen after 
poisoning with organophosphates [1]. 
Specifically, they aim to define the 
pathophysiology of IMS, which was 
initially described in 1987 as an illness 
occurring after the resolution of acute 
cholinergic crises and associated with 
proximal muscle weakness [2]. Since 
this seminal article was published, 
there has been tremendous controversy 
in the toxicology world concerning 
the true definition and existence 
of IMS as an isolated entity [3,4]. 
Here, Jayawardane and colleagues 
further elucidate the nature of IMS 
by systematically recording repetitive 
nerve stimulation (RNS) patterns at 
the neuromuscular junction in patients 
poisoned with OPs.
The Initial Definition of IMS
In 1987, Senanayake and Karalliedde 
reported on ten patients who 
presented 24–96 hours after acute 
cholinergic crises from exposure 
to methamidophos, fenthion, 
dimethoate, and monocrotophos. 
These patients had acute muscle 
paralysis in the proximal limb muscles, 
neck flexors, motor cranial nerves, 
and respiratory muscles, and some 
required ventilatory support [2]. This 
particular constellation of signs was 
designated the intermediate syndrome. 
Over the ensuing years, other patients 
have presented with similar findings 
within 24–96 hours after exposure 
to organophosphates, and there has 
been substantial debate as to whether 
IMS, the syndrome defined on the 
basis of this group of patients, is a true 
syndrome or represents subtherapeutic 
oxime therapy. Although the clinical 
picture is well-defined, changes in the 
neurophysiology at the neuromuscular 
junction in IMS are poorly delineated. 
Jayawardane and colleagues have 
clearly described a large cohort of OP-
poisoned patients and delineated the 
electrophysiological abnormalities that 
occur at the neuromuscular junction in 
conjunction with the clinical entity of 
IMS [1]. 
Electrophysiological Recordings in 
Organophosphate Poisoning: The 
New Study
In the paper published in PLoS 
Medicine [1], the researchers describe 
results of a prospective observational 
study of 78 patients with symptomatic 
OP poisoning presenting to two 
hospitals in the Central Province of 
Sri Lanka between May 2005 and 
December 2006. All patients were 
treated under the same protocol, 
receiving a 10–15 mg bolus of atropine 
intravenously followed by 10–15 mg 
atropine infusion over 12 hours. 
Additional atropine was used to control 
signs and symptoms of muscarinic 
excess. Pralidoxime was given as a 1 
g infusion every 6 hours for 48 hours. 
All patients were assessed daily with 
a focused neurological exam. RNS of 
the right and left median and ulnar 
nerves was done at the bedside within 
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This Perspective discusses the following 
new study published in PLoS Medicine:
Jayawardane P, Dawson AH, Weerasinghe 
V, Karalliedde L, Buckley NA, et al. (2008) 
The spectrum of intermediate syndrome 
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Jayawardane and colleagues 
evaluate a cohort of 78 patients with 
organophosphate poisoning from Sri 
Lanka, and identify changes in repetitive 
nerve stimulation that precede, and may 
help predict, the onset of intermediate 
syndrome.
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24 hours of presentation in 69 of 78 
patients and then repeated daily until 
all abnormalities resolved. 
The Main Findings
Ten of 78 patients were diagnosed with 
IMS by the authors’ diagnostic criteria. 
An additional 30 of 78 patients showed 
varying degrees of weakness from 
electrophysiological changes and were 
designated as having an incomplete, or 
forme fruste variant of IMS. From these 
data, the researchers identified a series 
of stereotypic electrophysiological 
changes associated with IMS, and 
were able to correlate the progression 
of muscle weakness with the 
electrophysiological changes, including 
an alteration in the pattern when 
patients developed respiratory muscle 
failure. During the recovery phase, 
electrophysiological improvement 
preceded patient recovery on the 
basis of clinical findings. Motor nerve 
conduction velocity was normal in 60 
patients regardless of clinical weakness. 
The researchers were able to document 
no difference in treatment regimens 
between those who developed IMS 
or the forme fruste variant, and those 
who did not. Since one of ten patients 
with IMS and six of 30 patients with 
the spectrum disorder did not receive 
pralidoxime, and the remainder of 
patients did receive the standard dose 
of 1 g intravenously every 6 hours for 
48 hours, these data may suggest that 
pralidoxime dosing has less impact 
on the development of IMS than 
previously suggested.
What Do These Findings Mean?
In this study, a large cohort of OP-
poisoned patients were studied 
with electrophysiological tracings 
of sequential RNS in the proximal 
muscle groups. The data show 
that there is clear progression 
of electrophysiological changes 
that parallel the development of 
IMS, followed by a resolution of 
electrophysiological changes that may 
precede clinical improvement. These 
data help to document the existence 
of IMS as a clinical entity. If these 
distinctive electrophysiological changes 
are subsequently validated in further 
studies, they should lead to improved 
diagnostic and prognostic tools for 
clinical use in OP-poisoned patients. 
Limitations of the Study
Although this study shows that the 
IMS spectrum disorder is associated 
with a continuum of stereotypic RNS 
changes and is distinct from acute 
muscarinic cholinergic crises, it still 
does not clearly define the underlying 
cause of the disorder. There is a large 
contingent of clinicians who feel that 
oximes are not necessary to treat ill OP-
poisoned patients, and these physicians 
tend to use high-dose atropine and 
supportive care [5]. In this study, all 
patients received atropine, and seven 
of 78 patients received only atropine 
without pralidoxime. It is not clear 
whether the specific RNS findings in 
the atropine-only group differed from 
other individuals in the atropine plus 
oxime group The electrophysiological 
findings suggest that IMS represents 
a complex series of interactions 
and cannot be classified as a simple 
receptor block on one side of the 
synaptic cleft. Although beyond the 
scope of the study, sequential RNS 
tracings of patients before and after 
administration of high-dose oximes 
might delineate acetylcholine’s effect 
on the neuromuscular junction during 
IMS.
What Research Remains To Be 
Done?
The authors provide limited data 
to help establish the existence of 
IMS as a clinical entity distinct from 
the muscarinic cholinergic crises. 
One individual enrolled in the 
study was clearly cholinergic during 
development of clinical IMS findings, 
and several other patients developed 
transient muscarinic findings during 
development of IMS. The RNS tracings 
in these patients were no different from 
other patients without overt muscarinic 
findings. 
The study did not address the 
issue of oxime treatment on the 
development of IMS. There is at 
least one other study that has shown 
improved neck flexor function, 
morbidity, and mortality in patients 
receiving high-dose pralidoxime 
infusions [6]. All of the patients 
included were treated either without 
oximes or with low-dose intermittent 
oximes. A large randomized trial of 
OP-poisoned patients receiving no 
oximes, low-dose oximes, or high-dose 
oximes would be useful in establishing 
appropriate treatment in relation 
to reducing muscle weakness and 
mortality. In such a trial, studying 
additional outcomes such as RNS and 
nerve conduction, particularly phrenic 
nerve conduction velocity, would go 
a long way towards answering the 
question of whether IMS is a clearly 
defined entity, and whether oximes 
truly make a difference to patient 
outcome.  
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